Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.55 -2.5%	$2.29	$1.29 ▼ $7.85	$277.46M	1.3	1.48 million shs	269,766 shs
BMEA Biomea Fusion	$1.85 -4.9%	$1.88	$1.29 ▼ $13.07	$69.32M	-0.13	1.17 million shs	537,239 shs
DBVT DBV Technologies	$10.18 -0.4%	$9.63	$2.20 ▼ $12.78	$278.69M	-0.59	190,508 shs	16,870 shs
SGMT Sagimet Biosciences	$9.06 -4.3%	$5.81	$1.73 ▼ $10.43	$278.76M	3.35	1.09 million shs	274,978 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	+1.16%	-4.40%	+4.82%	+69.48%	-57.07%
BMEA Biomea Fusion	-3.00%	+14.79%	-17.80%	+12.14%	-63.33%
DBVT DBV Technologies	-2.07%	-3.94%	+16.22%	+43.89%	+164.40%
SGMT Sagimet Biosciences	-0.11%	+8.99%	+14.39%	+335.94%	+184.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	2.5267 of 5 stars	3.5	2.0	2.0	2.5	0.6
BMEA Biomea Fusion	3.3724 of 5 stars	3.6	4.0	2.7	2.5	0.6
DBVT DBV Technologies	4.0098 of 5 stars	4.4	5.0	2.3	2.5	0.6
SGMT Sagimet Biosciences	2.6551 of 5 stars	3.5	3.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	3.00	Buy	$12.50	391.16% Upside
BMEA Biomea Fusion	3.18	Buy	$21.40	1,059.89% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	44.96% Upside
SGMT Sagimet Biosciences	3.00	Buy	$26.60	193.76% Upside

Current Analyst Ratings Breakdown

Latest BMEA, SGMT, DBVT, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/2/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$2.75 per share	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$1.42 per share	N/A
DBVT DBV Technologies	$4.15M	67.16	N/A	N/A	$1.42 per share	7.17
SGMT Sagimet Biosciences	$2M	138.86	N/A	N/A	$5.08 per share	1.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.18	N/A	N/A	N/A	N/A	-54.45%	-46.56%	8/11/2025 (Estimated)
BMEA Biomea Fusion	-$138.43M	-$3.55	N/A	N/A	N/A	N/A	-197.71%	-134.84%	7/30/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.76	N/A	N/A	N/A	N/A	-35.21%	-34.09%	8/13/2025 (Estimated)

Latest BMEA, SGMT, DBVT, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ANNX Annexon	-$0.36	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	BMEA Biomea Fusion	-$0.64	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/12/2025	Q1 2025	ANNX Annexon	-$0.30	-$0.37	-$0.07	-$0.37	N/A	N/A
5/8/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	-$0.56	+$0.23	-$0.56	N/A	N/A
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	7.99	7.99
BMEA Biomea Fusion	N/A	2.25	2.25
DBVT DBV Technologies	N/A	0.72	0.72
SGMT Sagimet Biosciences	N/A	20.34	20.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
BMEA Biomea Fusion	96.72%
DBVT DBV Technologies	71.74%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	12.67%
BMEA Biomea Fusion	18.42%
DBVT DBV Technologies	1.44%
SGMT Sagimet Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.71 million	95.81 million	Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
SGMT Sagimet Biosciences	8	30.67 million	26.17 million	Optionable

BMEA, SGMT, DBVT, and ANNX Headlines

Recent News About These Companies

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by Analysts

July 1, 2025 | marketbeat.com

SGMT Sagimet Biosciences Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Sagimet Biosciences Inc News (SGMT) - Investing.com

June 27, 2025 | investing.com

Sagimet Biosciences Inc. (SGMT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Sagimet Biosciences Inc.

June 14, 2025 | wsj.com

Sagimet Biosciences updates executive compensation

June 12, 2025 | investing.com

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

June 11, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...

June 11, 2025 | morningstar.comM

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know

June 9, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

June 9, 2025 | globenewswire.com

Sagimet Biosciences Analyst Ratings

June 5, 2025 | benzinga.com

Sagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment

June 4, 2025 | marketwatch.com

Sagimet Biosciences shares soar on positive acne treatment trial results

June 4, 2025 | ca.investing.com

Sagimet partner Ascletis announces significant Phase III acne data

June 4, 2025 | thepharmaletter.comT

Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results

June 4, 2025 | msn.com

Sagimet climbs as acne therapy hits main goals in late-stage trial in China

June 4, 2025 | msn.com

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

June 4, 2025 | aol.comA

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

June 4, 2025 | seekingalpha.com

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

June 4, 2025 | globenewswire.com

Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment

May 24, 2025 | investing.com

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction ...

May 24, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, SGMT, DBVT, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$2.54 -0.07 (-2.49%)

As of 12:35 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Biomea Fusion NASDAQ:BMEA

$1.84 -0.10 (-4.90%)

As of 12:35 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

DBV Technologies NASDAQ:DBVT

$10.18 -0.05 (-0.44%)

As of 12:25 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Sagimet Biosciences NASDAQ:SGMT

$9.06 -0.41 (-4.28%)

As of 12:34 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time